A retrospective study comparing effectiveness of caladribine versus fingolimod in the treatment of highly active relapsing multiple sclerosis
Latest Information Update: 01 Jun 2022
At a glance
- Drugs Cladribine (Primary) ; Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms The MERLYN Study
Most Recent Events
- 26 Apr 2022 Results assessing effectiveness of Cladribine versus Fingolimod in the treatment of highly active Relapsing Multiple Sclerosis presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 06 Apr 2022 New trial record
- 26 Feb 2022 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022